Hosted on MSN2d
InnoCare Pharma receives approval for CLL/SLL combination therapy trial in China
China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...
Hosted on MSN9d
BMS’ Phase II trial of CAR T cell therapy meets primary endpoint
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...
Cure Today7d
Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
FiercePharma10d
Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in ...
BioSpace10d
BMS Positions Breyanzi for Another Indication as LOE Woes Mount
With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...
WebMD7d
FDA OKs Triple Combo for Advanced Large B-Cell Lymphoma
The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).
Healio3d
Regimen may become new standard for relapsed/refractory diffuse large B-cell lymphoma
The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...